Patent ID: 9623041
Date: 2017-04-18
CPC Classifications: A61K,C07K

Claim:
1. A drug delivery composition for treating a cancer in a subject comprising: a plurality of biologically active molecular modules comprising at least one module that targets a tumorigenic cell or a cancer cell, at least one module that inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein in the tumorigenic cell or the cancer cell, and at least one module for cytoplasmic delivery, wherein the at least one module that targets a tumorigenic cell or a cancer cell includes trastuzumab and an antibody specific for a tumor vasculature protein, and the at least one module that inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein is a Morpholino AON having a sequence selected from the group consisting of: and a polymalic acid-based molecular scaffold, wherein the molecular modules are covalently linked to the scaffold.